Skip to main content
Clinical Trials/NCT06444139
NCT06444139
Completed
Not Applicable

A Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy of Probiotics on Gastrointestinal Function in Adults With Occasional Constipation

Probi AB1 site in 1 country100 target enrollmentJune 25, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gut Function
Sponsor
Probi AB
Enrollment
100
Locations
1
Primary Endpoint
Transit time
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

The goal of this clinical trial is to study the effect of probiotics on gut function in subjects with occasional constipation. The main question it aim to answer is if intake of probiotics will decrease the transit time. Participants will randomized to either consume probiotics or a placebo product.

Registry
clinicaltrials.gov
Start Date
June 25, 2024
End Date
December 13, 2024
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Probi AB
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females aged 18 - 65 years
  • With occasional constipation
  • Agrees to maintain current lifestyle habits
  • Provided voluntary, written, informed consent to participate in the study

Exclusion Criteria

  • Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  • Allergy, sensitivity, or intolerance to study products or clinical assessment materials
  • Chronic constipation
  • Current or history of significant diseases or abnormalities of the gastrointestinal tract (examples (include but are not limited to atrophic gastritis, celiac disease, gluten intolerance/sensitivity, inflammatory bowel disease)
  • Unstable metabolic disease or chronic diseases
  • Unstable hypertension.
  • Type I or Type II diabetes, cancer
  • Significant cardiovascular event in the past 6 months. History of or current diagnosis with kidney and/or liver diseases
  • Self-reported confirmation of current or pre-existing thyroid condition.
  • Individuals with an autoimmune disease or are immune compromised

Outcomes

Primary Outcomes

Transit time

Time Frame: Baseline to day 56

Difference in change in gut transit time as assessed by blue-dye method

Secondary Outcomes

  • Bowel movements(Baseline to day 28 and day 56)
  • Stool consistency(Baseline to day 28 and day 56)
  • Bloating and flatulence(Baseline to day 28 and day 56)
  • Quality of life(Baseline to day 28 and day 56)
  • Digestive symptoms(Baseline to day 28 and 56)

Study Sites (1)

Loading locations...

Similar Trials